Laurent Chardonnet - 07 Feb 2023 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Chief Financial Officer
Signature
/s/ Laurent Chardonnet
Issuer symbol
PRLD
Transactions as of
07 Feb 2023
Transactions value $
$0
Form type
4
Filing time
09 Feb 2023, 15:07:56
Previous filing
22 Dec 2022
Next filing
25 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (right to buy) Award $0 +135K $0.00 135K 07 Feb 2023 Common Stock 135K $7.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.